Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pyruvic Acid | 23 | 2022 | 203 | 2.410 |
Why?
|
| Magnetic Resonance Spectroscopy | 27 | 2023 | 3770 | 1.710 |
Why?
|
| Carbon Isotopes | 29 | 2013 | 458 | 1.490 |
Why?
|
| Magnetic Resonance Imaging | 43 | 2023 | 36415 | 0.790 |
Why?
|
| Metronidazole | 1 | 2023 | 232 | 0.780 |
Why?
|
| Pyruvates | 7 | 2013 | 83 | 0.600 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 2024 | 0.430 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 1457 | 0.390 |
Why?
|
| Alanine | 9 | 2012 | 608 | 0.350 |
Why?
|
| Rats, Wistar | 15 | 2013 | 1848 | 0.320 |
Why?
|
| Lactic Acid | 10 | 2012 | 1139 | 0.320 |
Why?
|
| Phantoms, Imaging | 11 | 2022 | 2513 | 0.320 |
Why?
|
| Rats | 27 | 2023 | 23705 | 0.300 |
Why?
|
| Image Enhancement | 7 | 2013 | 2888 | 0.290 |
Why?
|
| Gyrus Cinguli | 3 | 2022 | 1114 | 0.280 |
Why?
|
| Brain Neoplasms | 7 | 2021 | 9025 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 7407 | 0.240 |
Why?
|
| Kidney | 7 | 2017 | 7033 | 0.240 |
Why?
|
| Radiopharmaceuticals | 5 | 2012 | 2684 | 0.230 |
Why?
|
| Lactates | 3 | 2022 | 401 | 0.230 |
Why?
|
| Somatosensory Cortex | 2 | 2009 | 512 | 0.220 |
Why?
|
| Algorithms | 11 | 2018 | 14025 | 0.220 |
Why?
|
| Lactate Dehydrogenases | 1 | 2022 | 26 | 0.200 |
Why?
|
| Pain Threshold | 2 | 2003 | 603 | 0.200 |
Why?
|
| Brain | 14 | 2022 | 27094 | 0.200 |
Why?
|
| Reference Values | 5 | 2022 | 4921 | 0.190 |
Why?
|
| Hexokinase | 1 | 2022 | 124 | 0.190 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 185 | 0.190 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2019 | 3366 | 0.190 |
Why?
|
| Imaging, Three-Dimensional | 6 | 2013 | 4052 | 0.190 |
Why?
|
| Solubility | 1 | 2023 | 1085 | 0.190 |
Why?
|
| Self-Assessment | 1 | 2003 | 399 | 0.180 |
Why?
|
| Inositol | 1 | 2021 | 215 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2010 | 2293 | 0.180 |
Why?
|
| Glioma | 4 | 2019 | 3452 | 0.180 |
Why?
|
| Cerebrovascular Circulation | 5 | 2022 | 2725 | 0.180 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2020 | 186 | 0.170 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2020 | 221 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 8606 | 0.160 |
Why?
|
| Gadolinium DTPA | 3 | 2017 | 823 | 0.160 |
Why?
|
| Liver | 5 | 2012 | 7512 | 0.160 |
Why?
|
| Glutamic Acid | 2 | 2022 | 1173 | 0.150 |
Why?
|
| Organometallic Compounds | 3 | 2017 | 647 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 10 | 2019 | 8998 | 0.150 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2017 | 1490 | 0.150 |
Why?
|
| Myocardium | 4 | 2022 | 4746 | 0.150 |
Why?
|
| Reproducibility of Results | 9 | 2022 | 20118 | 0.150 |
Why?
|
| Contrast Media | 8 | 2020 | 5311 | 0.150 |
Why?
|
| Animals | 33 | 2023 | 168089 | 0.140 |
Why?
|
| Perfusion Imaging | 1 | 2019 | 198 | 0.140 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 4310 | 0.140 |
Why?
|
| Tissue Distribution | 6 | 2012 | 2263 | 0.140 |
Why?
|
| Carbon Radioisotopes | 3 | 2013 | 562 | 0.140 |
Why?
|
| Capillary Permeability | 1 | 2019 | 773 | 0.130 |
Why?
|
| Mice, Nude | 1 | 2022 | 3606 | 0.130 |
Why?
|
| Glioblastoma | 2 | 2021 | 3482 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2017 | 1432 | 0.120 |
Why?
|
| Manganese | 1 | 2017 | 391 | 0.120 |
Why?
|
| Breast | 3 | 2017 | 1964 | 0.120 |
Why?
|
| Ethanol | 2 | 2012 | 1322 | 0.120 |
Why?
|
| Caffeine | 3 | 2003 | 701 | 0.110 |
Why?
|
| Spin Labels | 3 | 2022 | 337 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2000 | 1084 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 2455 | 0.110 |
Why?
|
| Sodium Lactate | 1 | 2012 | 3 | 0.110 |
Why?
|
| Caproates | 1 | 2012 | 19 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 2426 | 0.100 |
Why?
|
| Prefrontal Cortex | 1 | 2003 | 2219 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 146 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 2047 | 0.100 |
Why?
|
| Brain Mapping | 4 | 2009 | 6635 | 0.090 |
Why?
|
| Physics | 1 | 2011 | 92 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2012 | 8164 | 0.090 |
Why?
|
| tau Proteins | 1 | 2021 | 2094 | 0.090 |
Why?
|
| Least-Squares Analysis | 2 | 2007 | 368 | 0.090 |
Why?
|
| Sensitivity and Specificity | 7 | 2012 | 14675 | 0.080 |
Why?
|
| Isoflurane | 1 | 2012 | 384 | 0.080 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2012 | 509 | 0.080 |
Why?
|
| Pain | 2 | 2003 | 5072 | 0.080 |
Why?
|
| Arthritis, Experimental | 1 | 2011 | 291 | 0.080 |
Why?
|
| Language Disorders | 1 | 2009 | 140 | 0.080 |
Why?
|
| Anesthetics, General | 1 | 2010 | 151 | 0.080 |
Why?
|
| Echo-Planar Imaging | 1 | 2012 | 663 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3594 | 0.070 |
Why?
|
| Magnetics | 1 | 2010 | 598 | 0.070 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2009 | 247 | 0.070 |
Why?
|
| Amyloid beta-Peptides | 1 | 2021 | 3841 | 0.070 |
Why?
|
| Models, Biological | 5 | 2011 | 9458 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2021 | 6586 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 3 | 2012 | 362 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2012 | 1111 | 0.070 |
Why?
|
| Male | 34 | 2021 | 360703 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 974 | 0.070 |
Why?
|
| Motion | 3 | 2005 | 779 | 0.070 |
Why?
|
| Humans | 32 | 2022 | 761222 | 0.060 |
Why?
|
| Equipment Failure Analysis | 2 | 2010 | 846 | 0.060 |
Why?
|
| Molecular Imaging | 1 | 2012 | 818 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5665 | 0.060 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2009 | 388 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2007 | 609 | 0.060 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2009 | 354 | 0.060 |
Why?
|
| Coma | 1 | 2009 | 484 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 9278 | 0.060 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 6341 | 0.060 |
Why?
|
| Kinetics | 4 | 2012 | 6312 | 0.050 |
Why?
|
| Artifacts | 4 | 2012 | 1912 | 0.050 |
Why?
|
| Mitochondria | 2 | 2013 | 3620 | 0.050 |
Why?
|
| Human Experimentation | 1 | 2003 | 123 | 0.050 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2022 | 72 | 0.050 |
Why?
|
| Coffee | 2 | 2003 | 593 | 0.050 |
Why?
|
| Acetazolamide | 1 | 2002 | 96 | 0.050 |
Why?
|
| Temporal Lobe | 1 | 2009 | 1695 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2009 | 11101 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5321 | 0.050 |
Why?
|
| Electromagnetic Fields | 1 | 2003 | 289 | 0.050 |
Why?
|
| Oxygen | 3 | 2022 | 4228 | 0.050 |
Why?
|
| Auditory Cortex | 2 | 2003 | 364 | 0.050 |
Why?
|
| Ketones | 1 | 2022 | 182 | 0.050 |
Why?
|
| Mice | 5 | 2022 | 81330 | 0.050 |
Why?
|
| Neuronal Plasticity | 1 | 2009 | 1432 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2009 | 1560 | 0.050 |
Why?
|
| Rotation | 3 | 2009 | 517 | 0.040 |
Why?
|
| Visual Cortex | 3 | 2003 | 1104 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 2003 | 479 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 94 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2020 | 522 | 0.040 |
Why?
|
| Adult | 14 | 2022 | 221120 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11733 | 0.040 |
Why?
|
| Disease Models, Animal | 4 | 2011 | 18222 | 0.040 |
Why?
|
| Leg | 1 | 2003 | 1087 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2003 | 1736 | 0.040 |
Why?
|
| Heart Failure | 1 | 2022 | 11701 | 0.040 |
Why?
|
| Arousal | 1 | 2003 | 1171 | 0.040 |
Why?
|
| Nerve Net | 1 | 2009 | 2288 | 0.040 |
Why?
|
| Tretinoin | 1 | 2020 | 517 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2002 | 750 | 0.040 |
Why?
|
| Whole Body Imaging | 2 | 2010 | 282 | 0.030 |
Why?
|
| Female | 17 | 2021 | 392552 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2003 | 1867 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 296 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2003 | 1434 | 0.030 |
Why?
|
| Half-Life | 1 | 2017 | 649 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2020 | 1518 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2003 | 3549 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 1988 | 0.030 |
Why?
|
| Renal Artery | 1 | 2017 | 351 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2022 | 1139 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 15308 | 0.030 |
Why?
|
| Papio | 1 | 2017 | 669 | 0.030 |
Why?
|
| Middle Aged | 12 | 2021 | 220858 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13386 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2000 | 20982 | 0.030 |
Why?
|
| Breast Diseases | 1 | 1998 | 443 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2643 | 0.030 |
Why?
|
| Reference Standards | 1 | 2019 | 1005 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 8002 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 2017 | 625 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2022 | 1807 | 0.030 |
Why?
|
| Time Factors | 5 | 2013 | 39957 | 0.030 |
Why?
|
| Acoustic Stimulation | 3 | 2003 | 1240 | 0.030 |
Why?
|
| Acetoacetates | 1 | 2013 | 19 | 0.030 |
Why?
|
| Acetylcarnitine | 1 | 2013 | 9 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2002 | 1176 | 0.030 |
Why?
|
| Dobutamine | 1 | 2013 | 116 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2019 | 1436 | 0.030 |
Why?
|
| Aged | 7 | 2022 | 169292 | 0.030 |
Why?
|
| Meglumine | 1 | 2013 | 144 | 0.030 |
Why?
|
| Acetyl Coenzyme A | 1 | 2013 | 74 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2007 | 5081 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2003 | 4165 | 0.030 |
Why?
|
| Disulfiram | 1 | 2012 | 63 | 0.030 |
Why?
|
| Functional Laterality | 2 | 2009 | 2257 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 5842 | 0.030 |
Why?
|
| Photic Stimulation | 3 | 2003 | 1984 | 0.020 |
Why?
|
| RNA Interference | 1 | 2020 | 2816 | 0.020 |
Why?
|
| Software | 2 | 2019 | 4431 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2022 | 2877 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2020 | 4111 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 3412 | 0.020 |
Why?
|
| Monocytes | 1 | 2020 | 2570 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4342 | 0.020 |
Why?
|
| Tritium | 1 | 2011 | 706 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 6504 | 0.020 |
Why?
|
| Bicarbonates | 1 | 2011 | 292 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2011 | 245 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2012 | 1159 | 0.020 |
Why?
|
| Single-Blind Method | 2 | 2003 | 1577 | 0.020 |
Why?
|
| Prostate | 1 | 2017 | 1772 | 0.020 |
Why?
|
| Language Tests | 1 | 2009 | 190 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2009 | 104 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 5773 | 0.020 |
Why?
|
| Median Nerve | 1 | 2009 | 131 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 790 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2003 | 6567 | 0.020 |
Why?
|
| Computer Systems | 1 | 2009 | 470 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2012 | 1963 | 0.020 |
Why?
|
| Anesthetics, Inhalation | 1 | 2012 | 573 | 0.020 |
Why?
|
| Physical Stimulation | 1 | 2009 | 517 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2003 | 5775 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 1376 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3875 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 22128 | 0.020 |
Why?
|
| Neoplasms | 2 | 2017 | 22142 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2009 | 9520 | 0.020 |
Why?
|
| Gadolinium | 1 | 2011 | 961 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 2081 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2854 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 14610 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 7386 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 6125 | 0.020 |
Why?
|
| Metabolome | 1 | 2012 | 989 | 0.010 |
Why?
|
| Calibration | 1 | 2007 | 819 | 0.010 |
Why?
|
| Speech Perception | 1 | 2009 | 508 | 0.010 |
Why?
|
| Speech | 1 | 2009 | 554 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 1028 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 2009 | 58952 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4567 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 2009 | 1416 | 0.010 |
Why?
|
| Fasting | 1 | 2009 | 1603 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2020 | 11512 | 0.010 |
Why?
|
| Equipment Design | 1 | 2010 | 3510 | 0.010 |
Why?
|
| Fixation, Ocular | 1 | 2002 | 242 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 10756 | 0.010 |
Why?
|
| Diffusion | 1 | 2002 | 813 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2003 | 1498 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2009 | 2981 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29688 | 0.010 |
Why?
|
| Anisotropy | 1 | 2002 | 1284 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2009 | 3056 | 0.010 |
Why?
|
| Neurosurgical Procedures | 1 | 2009 | 2067 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5250 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2000 | 958 | 0.010 |
Why?
|
| Cadaver | 1 | 2002 | 1358 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 41496 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13632 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 11067 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 54437 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2009 | 6224 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 16954 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 12728 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 8531 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 8642 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2003 | 6345 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1998 | 791 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 80675 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 10759 | 0.010 |
Why?
|
| ROC Curve | 1 | 1998 | 3584 | 0.010 |
Why?
|
| United States | 1 | 2018 | 72341 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 12341 | 0.000 |
Why?
|
| Adolescent | 2 | 2009 | 88300 | 0.000 |
Why?
|
| Diet | 1 | 2002 | 8048 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2009 | 64681 | 0.000 |
Why?
|
Concepts
(252)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(44)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_